JP2014514579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514579A5 JP2014514579A5 JP2014508592A JP2014508592A JP2014514579A5 JP 2014514579 A5 JP2014514579 A5 JP 2014514579A5 JP 2014508592 A JP2014508592 A JP 2014508592A JP 2014508592 A JP2014508592 A JP 2014508592A JP 2014514579 A5 JP2014514579 A5 JP 2014514579A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481066P | 2011-04-29 | 2011-04-29 | |
| US61/481,066 | 2011-04-29 | ||
| US201161511986P | 2011-07-26 | 2011-07-26 | |
| US61/511,986 | 2011-07-26 | ||
| US201161579600P | 2011-12-22 | 2011-12-22 | |
| US61/579,600 | 2011-12-22 | ||
| PCT/US2012/035429 WO2012149299A2 (en) | 2011-04-29 | 2012-04-27 | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016187730A Division JP6389217B2 (ja) | 2011-04-29 | 2016-09-27 | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514579A JP2014514579A (ja) | 2014-06-19 |
| JP2014514579A5 true JP2014514579A5 (ja) | 2015-01-15 |
| JP6016892B2 JP6016892B2 (ja) | 2016-10-26 |
Family
ID=46210410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508592A Active JP6016892B2 (ja) | 2011-04-29 | 2012-04-27 | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
| JP2016187730A Active JP6389217B2 (ja) | 2011-04-29 | 2016-09-27 | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016187730A Active JP6389217B2 (ja) | 2011-04-29 | 2016-09-27 | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9365640B2 (ja) |
| EP (2) | EP3096142A3 (ja) |
| JP (2) | JP6016892B2 (ja) |
| KR (1) | KR20140024914A (ja) |
| CN (1) | CN103688176A (ja) |
| AU (2) | AU2012249491B2 (ja) |
| CA (1) | CA2834535A1 (ja) |
| IL (1) | IL229114B (ja) |
| MX (1) | MX353482B (ja) |
| WO (1) | WO2012149299A2 (ja) |
| ZA (1) | ZA201308111B (ja) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| EP2683384B1 (en) * | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2699810T3 (es) | 2012-06-29 | 2019-02-12 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon |
| US9587281B2 (en) * | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| CN104755472A (zh) | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
| BR112015005243A2 (pt) | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
| JP2015535291A (ja) * | 2012-11-05 | 2015-12-10 | セルジーン コーポレイション | 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| JP2016521280A (ja) * | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
| EP3066215B1 (en) * | 2013-11-06 | 2019-04-24 | The United States of America, represented by the Secretary, Department of Health and Human Services | Method for subtyping lymphoma types by means of expression profiling |
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| BR112016012792A2 (pt) * | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
| CA2932120C (en) * | 2013-12-06 | 2023-09-19 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| CA2936907C (en) | 2014-02-14 | 2022-06-07 | Arkansas Children's Hospital Research Institute, Inc. | Acetaminophen protein adducts and methods of use thereof |
| AU2015240454B2 (en) | 2014-04-04 | 2019-08-22 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| KR20210132233A (ko) * | 2014-04-14 | 2021-11-03 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| WO2016018978A1 (en) | 2014-07-29 | 2016-02-04 | Mayo Foundation For Medical Education And Research | Quantifying monoclonal antibody therapeutics by lc-ms/ms |
| JP2017533727A (ja) * | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| EP3227681B1 (en) * | 2014-12-03 | 2020-10-21 | Bioventures, LLC | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| GB2533552B (en) * | 2014-12-11 | 2019-09-04 | Abcam Plc | A method for producing a recombinant allotype-specific rabbit monoclonal antibody |
| US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CA2982536C (en) | 2015-04-17 | 2023-04-18 | Spring Bioscience Corporation | Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a |
| US10338077B2 (en) * | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
| GB201512133D0 (en) * | 2015-07-10 | 2015-08-19 | Bergenbio As | Biomarkers |
| EP3334844A4 (en) * | 2015-08-12 | 2019-11-06 | Celgene Corporation | METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017044793A1 (en) * | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| JP6968058B2 (ja) | 2015-09-24 | 2021-11-17 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 質量分析法による免疫グロブリン遊離軽鎖の同定 |
| EP3352756A1 (en) | 2015-09-25 | 2018-08-01 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR20180095094A (ko) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| JP2019506897A (ja) | 2016-01-19 | 2019-03-14 | セルジーン コーポレイション | ヒトのセレブロンを発現するトランスジェニックマウス |
| US11028138B2 (en) * | 2016-07-02 | 2021-06-08 | Virongy L.L.C. | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
| EP3523647A4 (en) | 2016-09-07 | 2020-05-27 | Mayo Foundation for Medical Education and Research | IDENTIFICATION AND MONITORING OF MOLECULAR MASS CLAVED IMMUNOGLOBULINS |
| KR102173463B1 (ko) | 2016-10-11 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
| US11458123B2 (en) | 2016-11-01 | 2022-10-04 | Arvinas Operations, Inc. | Tau-protein targeting PROTACs and associated methods of use |
| KR20190082989A (ko) | 2016-12-01 | 2019-07-10 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| AU2017382406A1 (en) | 2016-12-23 | 2019-04-18 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
| MX2019007649A (es) | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| CN117551089A (zh) | 2017-01-26 | 2024-02-13 | 阿尔维纳斯运营股份有限公司 | 雌激素受体蛋白水解调节剂及相关使用方法 |
| WO2018144445A1 (en) * | 2017-01-31 | 2018-08-09 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| EP3577459A4 (en) | 2017-02-03 | 2020-12-16 | Celgene Corporation | METHOD OF MEASURING THE AFFINITY OF SMALL MOLECULES FOR CEREBLON |
| GB201710620D0 (en) * | 2017-07-03 | 2017-08-16 | Glaxosmithkline Intellectual Property Ltd | Targeted protein degradation |
| KR102050774B1 (ko) | 2017-08-14 | 2019-12-02 | 충남대학교산학협력단 | 세레브론 단백질 또는 이를 코딩하는 유전자를 포함하는 근육 손상으로 유도된 근육 질환의 예방 또는 치료용 조성물 |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| WO2019078522A1 (ko) * | 2017-10-20 | 2019-04-25 | 한국화학연구원 | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| CN112218859A (zh) | 2018-04-04 | 2021-01-12 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| WO2020197227A1 (ko) * | 2019-03-22 | 2020-10-01 | 울산대학교 산학협력단 | 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체 |
| WO2020227183A1 (en) * | 2019-05-03 | 2020-11-12 | Dynamic Biologics Inc. | Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| AU2020372333A1 (en) * | 2019-10-21 | 2022-04-28 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| TW202136240A (zh) | 2019-12-19 | 2021-10-01 | 美商亞文納營運公司 | 用於靶向降解雄激素受體之化合物及方法 |
| KR102311390B1 (ko) * | 2020-03-03 | 2021-10-13 | 이화여자대학교 산학협력단 | 교모세포종 예후예측용 조성물 |
| EP4126966A1 (en) * | 2020-03-31 | 2023-02-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| KR102555483B1 (ko) * | 2020-06-29 | 2023-07-14 | 고려대학교 산학협력단 | 다발골수종에서 혈액 표지자를 이용한 세레블론 발현 예측 방법 |
| WO2023151635A1 (zh) * | 2022-02-14 | 2023-08-17 | 标新生物医药科技(上海)有限公司 | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ATE205542T1 (de) | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5573758A (en) | 1995-04-28 | 1996-11-12 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| ES2529190T3 (es) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| BR9908811A (pt) | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
| US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
| ATE306469T1 (de) | 1999-03-18 | 2005-10-15 | Celgene Corp | Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| AU3074001A (en) | 1999-12-09 | 2001-06-18 | Advanced Research And Technology Institute, Inc. | Fluorescent in situ rt-pcr |
| AU2001274888A1 (en) * | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| ES2290091T3 (es) | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | Sintesis de enantiomeros de 4-amino-talidomida. |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｐｃｒ法 |
| US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| EP1924250B1 (en) | 2004-12-01 | 2017-01-04 | Celgene Corporation | Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| JP2008528514A (ja) | 2005-01-25 | 2008-07-31 | セルジーン・コーポレーション | ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物 |
| US7776551B2 (en) | 2005-07-12 | 2010-08-17 | Ramot At Tel Aviv University Ltd. | Methods and kits for diagnosing and treating mental retardation |
| CA2899923A1 (en) | 2005-08-31 | 2007-03-08 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| WO2007084992A2 (en) | 2006-01-19 | 2007-07-26 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| AU2007227664A1 (en) | 2006-03-13 | 2007-09-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US20100284915A1 (en) | 2006-06-30 | 2010-11-11 | Hongyue Dai | Genes associated with chemotherapy response and uses thereof |
| WO2008039475A2 (en) * | 2006-09-26 | 2008-04-03 | The Board Of Trustees Of The University Of Arkansas | A gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof |
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| EP2179037A4 (en) * | 2007-08-21 | 2010-12-22 | Nodality Inc | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES |
| US20090148853A1 (en) | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| US20100021437A1 (en) | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
| CA2725551C (en) | 2008-05-26 | 2017-06-06 | Yeda Research And Development Co. Ltd. | Methods of treating cancer of the central nervous system |
| EP2419727A1 (en) | 2009-04-14 | 2012-02-22 | Schering Corporation | Interferon-alfa sensitivity biomarkers |
| JP5645816B2 (ja) * | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| AU2010309035B2 (en) * | 2009-10-20 | 2014-01-30 | Fujimoto Pharmaceutical Corporation | Screening method utilizing thalidomide-targeting factor |
| MX337169B (es) | 2010-02-11 | 2016-02-16 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos. |
| US20110208433A1 (en) * | 2010-02-24 | 2011-08-25 | Biodesix, Inc. | Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples |
| MX2012010367A (es) | 2010-03-12 | 2012-11-23 | Celgene Corp | Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor. |
| SG10201610027VA (en) | 2010-09-15 | 2017-01-27 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| EP3266452B1 (en) * | 2011-03-11 | 2019-07-03 | Mayo Foundation for Medical Education and Research | Means to treat myelomas which are resistant to thalidomide, lenalidomide or pomalidomide |
| SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| WO2012153187A2 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| WO2014028445A2 (en) | 2012-08-14 | 2014-02-20 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
-
2012
- 2012-04-27 WO PCT/US2012/035429 patent/WO2012149299A2/en active Application Filing
- 2012-04-27 KR KR1020137031674A patent/KR20140024914A/ko not_active Application Discontinuation
- 2012-04-27 AU AU2012249491A patent/AU2012249491B2/en active Active
- 2012-04-27 EP EP16166884.3A patent/EP3096142A3/en not_active Withdrawn
- 2012-04-27 CA CA2834535A patent/CA2834535A1/en not_active Abandoned
- 2012-04-27 CN CN201280032778.XA patent/CN103688176A/zh active Pending
- 2012-04-27 MX MX2013012564A patent/MX353482B/es active IP Right Grant
- 2012-04-27 EP EP12726264.0A patent/EP2702410A2/en not_active Withdrawn
- 2012-04-27 US US13/459,005 patent/US9365640B2/en active Active
- 2012-04-27 JP JP2014508592A patent/JP6016892B2/ja active Active
-
2013
- 2013-10-28 IL IL229114A patent/IL229114B/en active IP Right Grant
- 2013-10-30 ZA ZA2013/08111A patent/ZA201308111B/en unknown
-
2016
- 2016-05-09 US US15/150,227 patent/US10047151B2/en active Active
- 2016-09-27 JP JP2016187730A patent/JP6389217B2/ja active Active
-
2017
- 2017-03-10 AU AU2017201674A patent/AU2017201674A1/en not_active Abandoned